Vanda Pinto, PhD, science writer —

Vanda is a biochemist with a PhD in biomedicine from the University of Porto, Portugal. She conducted her postdoctoral research first at the Bristol Medical School, U.K., studying the insulin-PI3K/Akt signaling pathway in diabetic nephropathy, then at the Institute of Molecular Pathology and Immunology of the University of Porto, where her focus was on glycosylation in lupus nephritis and inflammatory bowel disease. She next made the switch to science publishing, handling papers in biochemistry, molecular biology, and immunology.

Articles by Vanda Pinto

July 11, 2022 by Vanda Pinto, PhD

Talquetamab Named a Breakthrough Therapy for Hard-to-treat Myeloma

Talquetamab, a first-in-class antibody treatment being developed by Janssen Research & Development, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for hard-to-treat multiple myeloma. The designation was awarded based on the positive safety and efficacy findings of a Phase 1/2 clinical trial involving adults…

May 2, 2022 by Vanda Pinto, PhD

Agreement Reached to Develop MMP-13 Inhibitors to Treat Myeloma

SteroTherapeutics has entered into an exclusive license agreement with Moffitt Cancer Center and Florida Atlantic University Research Corporation to develop matrix metalloproteinase 13 (MMP-13) inhibitors for treating multiple myeloma. “This partnership with Moffitt Cancer Center and the Research Institute of Florida Atlantic University will allow us to…

Recent Posts